Trelegy Ellipta

DEVICE2 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Unknown Phase

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

CompletedNCT05127304

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2021-02-26End: 2022-02-03Updated: 2023-11-13

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT05169424

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2021-12-17End: 2021-12-27Updated: 2023-10-19

Related Papers

Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment–Naive Patients with COPD in the US

International Journal of COPD2025-02-011 citations

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol

Journal of Managed Care & Specialty Pharmacy2023-05-036 citations